Microbiota-derived short chain fatty acids: Their role and mechanisms in viral infections

Feng, Chuanqi; Jin, Chengxun; Liu, Kexin; Yang, Zecheng

doi:10.1016/j.biopha.2023.114414

Cited by 9 publications

(6 citation statements)

References 214 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the main reasons for this difference, we can point to factors such as microbiota diversity, type of diet, and host genotype. 24 But in agreement with our findings, a study showed that propionate and butyrate do not play a role in the pathophysiology of SARS-CoV-2 infection. 25 Most of the studies indicate the positive role of SCFAs on the disease of COVID-19; however, some studies have not shown this effect.…”

Section: Discussionsupporting

confidence: 92%

“…Therefore, the findings related to propionate and butyrate in this study were not in agreement with the previous investigation. Among the main reasons for this difference, we can point to factors such as microbiota diversity, type of diet, and host genotype 24 . But in agreement with our findings, a study showed that propionate and butyrate do not play a role in the pathophysiology of SARS‐CoV‐2 infection 25 .…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Short‐chain fatty acids profile in patients with SARS‐CoV‐2: A case‐control study

Nabizadeh

Memar

Hamishehkar

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and Aims: SARS-CoV-2, as a new pandemic disease, affected the world.Short-chain fatty acids (SCFAs) such as acetic, propionic, and butyric acids are the main metabolites of human gut microbiota. The positive effects of SCFAs have been shown in infections caused by respiratory syncytial virus, adenovirus, influenza, and rhinovirus. Therefore, this study aimed to evaluate the concentration of SCFAs in patients with SARS-CoV-2 compared with the healthy group. Methods: This research was designed based on a case and control study. Twenty healthy individuals as the control group and 20 persons admitted to the hospital with a positive test of coronavirus disease (COVID-19) real-time polymerase chain reaction were included in the study as the patient group from September 2021 to October 2021, in Tabriz, Iran. Stool specimens were collected from volunteers, and analysis of SCFAs was carried out by a high-performance liquid chromatography system.Results: The amount of acetic acid in the healthy group was 67.88 ± 23.09 μmol/g, while in the group of patients with COVID-19 was 37.04 ± 13.29 μmol/g. Therefore, the concentration of acetic acid in the patient group was significantly (p < 0.001) lower than in the healthy group. Propionic and butyric acid were present in a higher amount in the control group compared with the case group; however, this value was not statistically significant (p > 0.05). Conclusion:This study showed that the concentration of acetic acid as the metabolite caused by gut microbiota is significantly disturbed in patients with COVID-19. Therefore, therapeutic interventions based on gut microbiota metabolites in future research may be effective against COVID-19.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 86%

Short‐chain fatty acids profile in patients with SARS‐CoV‐2: A case‐control study

Nabizadeh

Memar

Hamishehkar

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…This metabolite, already widely described as crucial for supporting the beneficial activities of probiotics, could therefore also play a role in boosting the antiviral activity. In vivo studies support a protective role of butyrate against viral infections [ 34 ]. On the other hand, the picture of in vitro settings is complicated by the different experimental combinations of cell lines and viruses, coupled to the fact that a direct involvement or modulation of the immune system (the major player in vivo) is lacking.…”

Section: Discussionmentioning

confidence: 99%

Vaginal Lactobacilli Supernatants Protect from Herpes Simplex Virus Type 1 Infection in Cell Culture Models

Avitabile,

Menotti,

Giordani

et al. 2024

IJMS

View full text Add to dashboard Cite

A healthy vaginal microbiota hosts Lactobacillus as the most predominant genus. Lactobacilli play a role in human health through the production of diverse antimicrobial substances that can act against human pathogens or modulate the immune system. Previous reports highlighted the ability of vaginal lactobacilli to counteract viruses causing STIs, e.g., HIV-1 and HSV-2. In this report, we analyze the activity of supernatants of vaginal lactobacilli against HSV-1 infection, which is becoming increasingly relevant as a STI. We show that the supernatants of two vaginal Lactobacillus species (i.e., L. crispatus and L. gasseri) were active at neutralizing HSV-1 infection in two different cell lines of human and simian origin. Specifically, we demonstrate that L. crispatus strains are the most effective in antiviral activity, as evidenced by the comparison with a vaginal pathogen taken as reference. The effect was specific and not attributable to the generic toxicity of the supernatants to the cells. Our results pave the way for the development of probiotics to limit the impact of HSV-1 infection on women’s health.

show abstract

“…SCFAs are produced by gut bacteria during the digestion of fiber. They can improve intestinal barrier function, reduce inflammation, and promote healthy immune function [ 31 , 101 ]. Bile acids, which are involved in the metabolism of fats, are produced by the liver and can be modified by gut bacteria [ 102 ].…”

Section: Probiotics and Their Metabolitesmentioning

confidence: 99%

The Networked Interaction between Probiotics and Intestine in Health and Disease: A Promising Success Story

Skoufou,

Tsigalou,

Vradelis

et al. 2024

Microorganisms

View full text Add to dashboard Cite

Probiotics are known to promote human health either precautionary in healthy individuals or therapeutically in patients suffering from certain ailments. Although this knowledge was empirical in past tomes, modern science has already verified it and expanded it to new limits. These microorganisms can be found in nature in various foods such as dairy products or in supplements formulated for clinical or preventive use. The current review examines the different mechanisms of action of the probiotic strains and how they interact with the organism of the host. Emphasis is put on the clinical therapeutic use of these beneficial microorganisms in various clinical conditions of the human gastrointestinal tract. Diseases of the gastrointestinal tract and particularly any malfunction and inflammation of the intestines seriously compromise the health of the whole organism. The interaction between the probiotic strains and the host’s microbiota can alleviate the clinical signs and symptoms while in some cases, in due course, it can intervene in the underlying pathology. Various safety issues of the use of probiotics are also discussed.

show abstract

Microbiota-derived short chain fatty acids: Their role and mechanisms in viral infections

Cited by 9 publications

References 214 publications

Short‐chain fatty acids profile in patients with SARS‐CoV‐2: A case‐control study

Short‐chain fatty acids profile in patients with SARS‐CoV‐2: A case‐control study

Vaginal Lactobacilli Supernatants Protect from Herpes Simplex Virus Type 1 Infection in Cell Culture Models

The Networked Interaction between Probiotics and Intestine in Health and Disease: A Promising Success Story

Contact Info

Product

Resources

About